Literature DB >> 6436182

A randomized double-blind investigation of cefroxadine (CGP 9000) versus cephalexin in urinary tract infection.

J Hess, P Gammelgaard, B Holst, F Rasmussen, V F Thomsen.   

Abstract

A total of 64 out-patients with significant urinary tract infection were randomly allocated to treatment with cefroxadine 250 mg q.i.d. or cephalexin 500 mg q.i.d. for ten days. Urine cultures were performed before allocation to the treatment groups and on Days 0, 1, 3, 7 and 21. Twenty patients discontinued treatment prematurely because of insignificant bacteriuria on Day 0. Both drug regimes--the cefroxadine dose was half that of cephalexin--showed good activity during treatment, and no statistically significant differences were found between the two drugs. At follow-up, several relapses were found in both treatment groups. Adverse drug reactions were only reported by three patients in the cefroxadine group, and by none in the cephalexin group.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436182     DOI: 10.1007/bf01645959

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  8 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  CGP 9000: a new orally active, broad-spectrum cephalosporin.

Authors:  O Zak; W A Vischer; C Schenk; W Tosch; W Zimmermann; J Regös; E R Suter; F Kradolfer; J Gelzer
Journal:  J Antibiot (Tokyo)       Date:  1976-06       Impact factor: 2.649

3.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

4.  Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function.

Authors:  M Ohkawa; K Takamae; M Shimamura; K Kuroda; S Awazu
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

5.  Pharmacokinetic comparison of cefroxadin (CGP 9000) and cephalexin by simultaneous administration to humans.

Authors:  J B Lecaillon; J L Hirtz; J P Schoeller; G Humbert; W Vischer
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Efficacy and tolerability of CGP 9,000 ("Oraspor') in diabetic patients treated for urinary tract infections: a case control study.

Authors:  M Kissling; M Xilinas; L Glaus
Journal:  Pharmatherapeutica       Date:  1981

7.  Pharmacokinetics of a new cephalosporin, CGP 9000 (cefroxadine), in healthy volunteers.

Authors:  T Bergan
Journal:  Chemotherapy       Date:  1980       Impact factor: 2.544

8.  Activity of cefroxadine and cephalexin in urinary tract infections: a double-blind comparative study.

Authors:  T Ahrens; K G Naber
Journal:  Infection       Date:  1983 Jan-Feb       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.